How a Chinese firm jumped to the front of the virus vaccine race

In May, CanSino became the first globally to publish a full scientific study on its early human trials, an important step because it allows researchers worldwide to assess a vaccine’s potential. The company is yet to generate revenue and logged a $22 million loss last year.

from International-News-Economic Times https://ift.tt/2C0UGZL
via IFTTT

SHARE